Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

164.34 -6.72 (-3.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,960,516
Open 169.33
Bid (Size) 164.67 (1)
Ask (Size) 164.98 (3)
Prev. Close 171.06
Today's Range 164.15 - 170.39
52wk Range 115.03 - 217.25
Shares Outstanding 387,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
 
Via Benzinga

Performance

YTD
-8.18%
-8.18%
1 Month
-10.66%
-10.66%
3 Month
+0.69%
+0.69%
6 Month
-5.70%
-5.70%
1 Year
+7.19%
+7.19%

More News

Read More
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Via The Motley Fool
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Via Benzinga
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
Via Benzinga
Is Moderna Stock a Buy Now?
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in 2023
Via The Motley Fool
Why Personalis Shares Are Trading Higher Today
Via Benzinga
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Via InvestorPlace
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
Via ACCESSWIRE
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
Via InvestorPlace
Novavax Shares Jumped in January While Others Slipped
Via MarketBeat
Exposures COVID-19 Product Safety
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Via The Motley Fool
This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now
Via The Motley Fool
Why BioNTech And Moderna Shares Are Falling After Pfizer News
Via Benzinga
Biden Administration Plans To End COVID-19 Public Health Emergency In May
Via Benzinga
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
Via Investor's Business Daily
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Via ACCESSWIRE
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Via The Motley Fool
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
Via Investor's Business Daily
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.